Cardio Diagnostics Holdings, Inc. (CDIOW)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-02

Key Insights

Paul Frederick Burton, a director of Cardio Diagnostics Holdings, Inc. (CDIO), acquired 3,205 stock options with an exercise price of $1.95 on March 31, 2026, which will expire on March 31, 2036.
This insider transaction suggests Burton may be bullish on the company's future prospects, as he is increasing his stake through this option grant.
The timing of the options grant, close to the company's current stock price, indicates the company may be compensating directors with incentive-based equity awards to align their interests with shareholders.

Insider Trading Filed: 2026-04-02

Key Insights

James Intrater, a director of Cardio Diagnostics Holdings, Inc., acquired 3,205 stock options with an exercise price of $1.95 on March 31, 2026, indicating insider confidence in the company's prospects.
The options have a 10-year term, expiring on March 31, 2036, suggesting a long-term commitment from the director.
This insider transaction could signal positive sentiment about the company's future performance and growth potential.

Insider Trading Filed: 2026-04-02

Key Insights

Wendy J. Betts, a director of Cardio Diagnostics Holdings, Inc., acquired 3,205 stock options with an exercise price of $1.95 on 03/31/2026.
This insider transaction represents a direct ownership increase of 9,513 shares, indicating potential confidence in the company's future prospects.
The timing of this option grant, close to the end of the quarter, may suggest an upcoming catalyst or development that the director expects to benefit the company.

Insider Trading Filed: 2026-04-02

Key Insights

Peter Fung, a director of Cardio Diagnostics Holdings, Inc., has acquired 3,205 stock options with an exercise price of $1.95 on March 31, 2026, signaling his confidence in the company's future.
The stock options acquired have a 10-year expiration date, indicating a long-term investment horizon for Fung in the company.
Fung's ownership of 9,513 stock options following this transaction suggests he holds a significant stake in the company, aligning his interests with those of shareholders.

Current Report Filed: 2026-02-19

Key Insights

Cardio Diagnostics is holding an investor call to discuss corporate updates, recent clinical data, reimbursement progress, and strategic initiatives.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
The presentation materials and remarks during the call contain forward-looking statements that are subject to risks and uncertainties described in the company's SEC filings.

Insider Trading Filed: 2026-01-06

Key Insights

Paul Frederick Burton, a director of Cardio Diagnostics Holdings, Inc. (CDIOW), acquired 2,306 stock options with an exercise price of $2.71 on 12/31/2025. This suggests potential confidence in the company's future performance by an insider.
The stock options acquired by Burton have a 10-year expiration date, indicating a long-term investment horizon and belief in the company's growth potential.
The acquisition of stock options by a director could signal upcoming corporate developments or strategic initiatives that the insider believes will drive the company's share price higher in the future.

Insider Trading Filed: 2026-01-06

Key Insights

Insider James Intrater acquired 2,306 stock options in Cardio Diagnostics Holdings, Inc. (CDIOW) on 12/31/2025, indicating his confidence in the company's future performance.
The options have an exercise price of $2.71 and expire on 12/31/2035, suggesting a long-term investment horizon.
Intrater's ownership stake in the company increased to 7,259 shares, representing a direct ownership in the company.

Insider Trading Filed: 2026-01-06

Key Insights

Wendy J Betts, a director of Cardio Diagnostics Holdings, Inc., acquired 2,306 stock options with an exercise price of $2.71 on 12/31/2025, increasing her total beneficial ownership to 6,308 options.
The stock option grant suggests Betts has a long-term commitment to the company and aligns her interests with shareholders.
The timing of the options grant, near the end of the year, may indicate the company is rewarding directors for their contributions or preparing for future growth initiatives.

Insider Trading Filed: 2026-01-06

Key Insights

Insider Peter Fung has acquired 2,306 stock options with an exercise price of $2.71, indicating his confidence in the company's future performance.
The option grant expiration date is 12 years from the transaction date, suggesting a long-term investment horizon for Fung.
Fung's role as a director suggests he has access to material non-public information and believes the company's stock is undervalued at the current price.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.